Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.

Literature DB >> 7397945

Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.

Abstract

In two patients with acute non-lymphocytic leukemia, leukemic cell as well as plasma concentrations of Daunorubicin (D) and Daunorubicinol (DOH) were studied after administration of D as free drug or as a complex with DNA. The peak plasma concentration of D was slightly higher after infusion of the D-DNA complex than after free drug while the intracellular pattern was the opposite. The intracellulr peak concentrations were found to be 50-100 fold higher and displayed a kinetic pattern which was completely different from that of D in plasma. We therefore suggest that assays of the concentrations of the drug and its toxic metabolite in leukemic cells are more relevant than the monitoring of plasma concentrations in the evaluation of the clinical effect of this drug's action.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1980 PMID： 7397945 DOI： 10.1007/bf00254020

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

12 in total

1. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors: W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

2. Daunorubicin metabolism by human hematological components.

Authors: D H Huffman; N R Bachur
Journal: Cancer Res Date: 1972-03 Impact factor: 12.701

3. Decreased cardiac toxicity of adriamycin and daunorubicin when bound to DNA.

Authors: A Langslet; I Oye; S O Lie
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1974-11

4. Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Authors: A Trouet; D Deprez-de Campeneere; C De Duve
Journal: Nat New Biol Date: 1972-09-27

5. Pharmacokinetics of methotrexate.

Authors: D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal: Clin Pharmacol Ther Date: 1973 Jul-Aug Impact factor: 6.875

6. Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

Authors: M Beran; B Andersson; S Eksborg; H Ehrsson
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

7. Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.

Authors: G Gahrton; M Björkholm; G Brenning; I Christenson; L Engstedt; S Franzén; B Gullbring; G Holm; C Högman; P Hörnsten; S Jameson; A Killander; C Simonsson-Lindemalm; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Paul; C Pauli; C Peterson; P Reizenstein; B Simonsson; K O Skårberg; A M Udén; B Wadman
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

8. Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

Authors: D Deprez-De Campeneere; R Baurain; M Huybrechts; A Trouet
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

9. Reversed-phase liquid chromatography of adriamycin and daunorubicin and their hydroxyl metabolites adriamycinol and daunorubicinol.

Authors: S Eksborg
Journal: J Chromatogr Date: 1978-02-11

4. Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

Authors: P Gunvén; N O Theve; C Peterson
Journal: Cancer Chemother Pharmacol Date: 1986 Impact factor: 3.333

4 in total